公开(公告)号：US20210047304A1

公开(公告)日：2021-02-18

申请号：US16883713

申请日：2020-05-26

Applicant: AbbVie Inc.

Inventor： Marlon Cowart ,  Steven Fidanze ,  Lisa Hasvold ,  Dachun Liu ,  Keith McDaniel ,  John Pratt ,  George Sheppard ,  Le Wang

IPC: C07D405/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D487/10

Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US09957263B2

公开(公告)日：2018-05-01

申请号：US14392201

申请日：2014-06-27

Applicant: AbbVie Inc.

Inventor： Yujia Dai ,  Steven D. Fidanze ,  Lisa Hasvold ,  James Holms ,  Dachun Liu ,  William McClellan ,  Keith McDaniel ,  Jasmina Marjanovic ,  George Sheppard ,  Le Wang

IPC: C07D471/02 ,  A61K31/44 ,  A61K31/497 ,  C07D471/04 ,  A61K45/06 ,  A61K31/437 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K31/4545 ,  A61K31/506

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K45/06

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.

公开(公告)号：US20160272630A1

公开(公告)日：2016-09-22

申请号：US14392201

申请日：2014-06-27

Applicant: ABBVIE INC.

Inventor： Yujia Dai ,  Steven D. Fidanze ,  Lisa Hasvold ,  James Holms ,  Dachun Liu ,  William McClellan ,  Keith McDaniel ,  Jasmina Marjanovic ,  George Sheppard ,  Le Wang

IPC: C07D471/04 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/497 ,  A61K31/506 ,  A61K31/551 ,  A61K31/437 ,  A61K31/496

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K45/06

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.

公开(公告)号：US20190382383A1

公开(公告)日：2019-12-19

申请号：US16341352

申请日：2016-10-14

Applicant: AbbVie Inc.

Inventor： Marlon Cowart ,  Steven Fidanze ,  Lisa Hasvold ,  Dachun Liu ,  Keith McDaniel ,  John Pratt ,  George Sheppard ,  Le Wang

IPC: C07D405/12 ,  C07D487/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: Provided herein are compounds of formula (I) wherein R1, Y, L1, G1, X1, X2, L2, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

公开(公告)号：US20190084981A1

公开(公告)日：2019-03-21

申请号：US16192927

申请日：2018-11-16

Applicant: AbbVie Inc.

Inventor： Yujia Dai ,  Steven D. Fidanze ,  Lisa Hasvold ,  James Holms ,  Dachun Liu ,  William McClellan ,  Keith McDaniel ,  Jasmina Marjanovic ,  George Sheppard ,  Le Wang

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/506 ,  A61K31/497 ,  A61K31/437 ,  A61K31/551 ,  A61K31/541 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/4545

Abstract: The present invention provides for compounds of formula (I) wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US09125913B2

公开(公告)日：2015-09-08

申请号：US14058159

申请日：2013-10-18

Applicant: AbbVie Inc.

Inventor： Milan Bruncko ,  Hong Ding ,  George A. Doherty ,  Steven W. Elmore ,  Lisa Hasvold ,  Laura A. Hexamer ,  Aaron R. Kunzer ,  Robert A. Mantei ,  William J. McClellan ,  Chang H. Park ,  Cheol-Min Park ,  Andrew M. Petros ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Gary T. Wang ,  Le Wang ,  Xilu Wang ,  Michael D. Wendt

IPC: A61K31/495 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5377 ,  C07D209/32 ,  C07D211/96 ,  C07D213/64 ,  C07D215/20 ,  C07D217/16 ,  C07D231/56 ,  C07D235/26 ,  C07D249/04 ,  C07D295/125 ,  C07D295/14 ,  C07D309/14 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D471/04 ,  A61K31/407 ,  A61K45/06 ,  C07D241/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D413/06 ,  C07D487/04

CPC classification number: C07D401/12 ,  A61K31/407 ,  A61K31/495 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/08 ,  C07D209/32 ,  C07D211/58 ,  C07D211/96 ,  C07D213/64 ,  C07D215/20 ,  C07D217/16 ,  C07D231/56 ,  C07D235/26 ,  C07D241/04 ,  C07D249/04 ,  C07D295/125 ,  C07D295/14 ,  C07D295/155 ,  C07D309/04 ,  C07D309/14 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Abstract translation: 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白的活性的化合物，含有该化合物的组合物和治疗疾病的方法，其中表达抗凋亡Bcl-2蛋白。

公开(公告)号：US20140107119A1

公开(公告)日：2014-04-17

申请号：US14081940

申请日：2013-11-15

Applicant: AbbVie Inc.

Inventor： Milan Bruncko ,  Hong Ding ,  George A. Doherty ,  Steven W. Elmore ,  Lisa Hasvold ,  Laura A. Hexamer ,  Aaron R. Kunzer ,  Robert A. Mantei ,  William J. McClellan ,  Chang H. Park ,  Cheol-Min Park ,  Andrew M. Petros ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-fu Tao ,  Gary T. Wang ,  Le Wang ,  Xilu Wang ,  Michael D. Wendt ,  Todd M. Hansen

IPC: A61K31/5377 ,  A61K31/496 ,  C07D295/155 ,  A61K45/06 ,  C07D215/14 ,  C07D405/12 ,  C07D209/20 ,  C07D309/32 ,  C07D231/56

CPC classification number: C07D215/14 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/20 ,  C07D209/32 ,  C07D211/96 ,  C07D213/64 ,  C07D215/20 ,  C07D217/16 ,  C07D231/56 ,  C07D235/26 ,  C07D249/04 ,  C07D295/125 ,  C07D295/13 ,  C07D295/14 ,  C07D295/155 ,  C07D309/08 ,  C07D309/14 ,  C07D309/32 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12 ,  C07D487/04

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

公开(公告)号：US20140057889A1

公开(公告)日：2014-02-27

申请号：US14058159

申请日：2013-10-18

Applicant: AbbVie Inc.

Inventor： Milan Bruncko ,  Hong Ding ,  George A. Doherty ,  Steven W. Elmore ,  Lisa Hasvold ,  Laura A. Hexamer ,  Aaron R. Kunzer ,  Robert A. Mantei ,  William J. McClellan ,  Chang H. Park ,  Cheol-Min Park ,  Andrew M. Petros ,  Xiaohong Song ,  Andrew J. Souers ,  Gerard M. Sullivan ,  Zhi-Fu Tao ,  Gary T. Wang ,  Le Wang ,  Xilu Wang ,  Michael D. Wendt

IPC: A61K31/5377 ,  A61K31/496 ,  C07D413/06 ,  C07D401/06 ,  A61K45/06 ,  A61K31/407 ,  C07D403/06 ,  A61K31/501 ,  C07D241/04 ,  A61K31/495 ,  C07D405/06 ,  C07D487/04

CPC classification number: C07D401/12 ,  A61K31/407 ,  A61K31/495 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/08 ,  C07D209/32 ,  C07D211/58 ,  C07D211/96 ,  C07D213/64 ,  C07D215/20 ,  C07D217/16 ,  C07D231/56 ,  C07D235/26 ,  C07D241/04 ,  C07D249/04 ,  C07D295/125 ,  C07D295/14 ,  C07D295/155 ,  C07D309/04 ,  C07D309/14 ,  C07D401/06 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Abstract translation: 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白活性的化合物，含有化合物的组合物和治疗疾病的方法，其中表达有抗凋亡Bcl-2蛋白。

公开(公告)号：US20210130346A1

公开(公告)日：2021-05-06

申请号：US16605039

申请日：2017-04-14

Applicant: AbbVie Inc.

Inventor： David Hardee ,  Jason Brewer ,  Lisa Hasvold ,  Dachun Liu ,  Keith McDaniel ,  Michael Schrimpf ,  George Sheppard

IPC: C07D471/04 ,  A61P35/04

Abstract: Compounds of formula (I), wherein R1, R2, R3, R5, R6, R7, A1, A2, A3, A4, X1, and X2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.

公开(公告)号：US20180296566A1

公开(公告)日：2018-10-18

申请号：US16012379

申请日：2018-06-19

Applicant: AbbVie Inc.

Inventor： Le Wang ,  John K. Pratt ,  Keith F. McDaniel ,  Yujia Dai ,  Steven D. Fidanze ,  Lisa Hasvold ,  James H. Holms ,  Warren M. Kati ,  Dachun Liu ,  Robert A. Mantei ,  William J. McClellan ,  George S. Sheppard ,  Carol K. Wada

IPC: A61K31/541 ,  A61K45/06 ,  C07D487/04 ,  C07D471/04 ,  A61K31/5025 ,  A61K31/437 ,  A61K31/5377

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).